BTCY - Biotricity, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.5400
-0.0325 (-5.68%)
As of 2:56PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close0.5725
Open0.5800
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.5200 - 0.6000
52 Week Range0.4220 - 4.4500
Volume17,038
Avg. Volume30,606
Market Cap19.344M
Beta (3Y Monthly)4.15
PE Ratio (TTM)N/A
EPS (TTM)-0.2570
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswirelast month

    Biotricity Doubles Sales Force – Expands Device Fleet by 59%

    Biotricity Inc. (OTCQB: BTCY), a medical diagnostic and consumer healthcare technology company, today announced that it has  expanded its fleet of Bioflux devices to meet customer demand. “Our sales expansion is yielding results and we see a consistent increase in sales as a result of our anchor clients recommending us to other medical professionals,” said Mr. Waqaas Al-Siddiq, Biotricity Founder and CEO. Long-term, we are a technology company with a pipeline of complimentary remote patient monitoring and pre-emptive diagnostic technologies that will allow us to leapfrog and build on our existing platform.

  • GlobeNewswire3 months ago

    Biotricity Provides Fiscal Fourth Quarter Update: Sales Force Expansion to Fuel Growth

    Biotricity Inc. (OTCQB: BTCY), a medical diagnostic and consumer healthcare technology company, today provided a progress report for its fiscal 2018 fourth quarter, which ended March 31, 2019. The company continues to execute its plans to grow its sales force, expand its geographic footprint, and reach more Americans with its life-saving technology. The company’s flagship product, Bioflux, was met with a high adoption rate in the clinical community throughout the soft launch of the past year, leading to positive customer feedback and steady re-order rates.

  • GlobeNewswire4 months ago

    Biotricity Achieves Market Expansion in Two New States

    Biotricity Inc. (OTCQB: BTCY), a medical diagnostic and consumer healthcare technology company, has expanded its sales team to cover two additional states in the US that are key to driving faster adoption of its flagship product, Bioflux. The Company has been experiencing great traction with its technology in the marketplace and is taking the opportunity to capitalize on its momentum and increase its regional footprint. The Company’s remote patient monitoring device Bioflux monitors a patient’s ECG in near real-time, constantly analyzing and collecting data on the device and periodically uploading to the cloud via embedded cellular technology.

  • GlobeNewswire4 months ago

    Biotricity Announces Expanded R&D Team for the Development of its Fetal/Maternal and Ambulatory Wellness Monitoring Systems

    Biotricity Inc. (OTCQB: BTCY), a medical diagnostic and consumer healthcare technology company, is pleased to announce further buildout of its R&D team, with the engagement of the Biomedical Engineering Department at the University of Calgary. The expanded team will include a Biomedical Engineering (BME) fellow under Dr. Ferber, Director of Biomedical Engineering’s Human Performance Laboratory, who will explore and develop effective representations of both fetal/maternal heart rate variability (HRV) and electro-hysterography (labor contraction monitoring) in pregnancy.

  • GlobeNewswire5 months ago

    Biotricity Achieves Significant Milestones for Both Fetal/Maternal and Ambulatory Wellness Monitoring Systems

    Biotricity, Inc. (OTCQB: BTCY), a medical diagnostic and consumer healthcare technology company dedicated to delivering innovative, biometric remote monitoring solutions, today announced that it has achieved significant progress in their University of Calgary-based R & D program for their latest wellness monitoring systems. Clinical data collection has commenced for both its fetal/maternal and ambulatory adult heart rate variability (HRV) monitoring systems. Dr. David Liepert, QA/QI and Safety Lead and Director for the University of Calgary Cumming School of Medicine Department of Anesthesia commented, “We could not be more excited to participate in developing both these non-invasive medical-grade ambulatory monitors, utilizing the amazing fidelity and mobility of the Bioflux system.

  • GlobeNewswire6 months ago

    Biotricity Provides End of Year Shareholder Update

    Biotricity Inc. (OTCQB: BTCY), a medical diagnostic and consumer healthcare technology company, is providing an end of year update to its shareholders. “2018 was an exciting year for Biotricity as we launched our first medical-grade device into the growing cardiac market and received great reception from our initial sales forays,” said Mr. Waqaas Al-Siddiq, Biotricity Founder and CEO. The Company experienced a 211% growth in sales from Q2 2018 to Q3 2018.

  • GlobeNewswire8 months ago

    Biotricity Actively Pursues Holter Market with Bioflux Product Offering

    Biotricity Inc. (OTCQB: BTCY), a medical diagnostic and consumer healthcare technology company, today announced that it will be actively pursuing the Holter market in addition to the MCT market with its Bioflux product offering, expanding its revenue growth opportunities. Bioflux is a 3 in 1 monitoring solution, offering mobile cardiac telemetry (MCT), event, and Holter monitoring.

  • GlobeNewswire8 months ago

    Biotricity Builds Capacity with University of Calgary and Receives Ethics Approvals for Research

    Biotricity Inc. (OTCQB: BTCY), a medical diagnostic and consumer healthcare technology company, today announced the launch of its 2019 R&D program at the University of Calgary. The Company is initiating a series of investigations using the 1000 Hz fidelity of Bioflux to facilitate ambulatory Heart Rate Variability (HRV) monitoring for maternity and in both major and emergency surgery patients at Rockyview General Hospital in Calgary. Successful results will open up two growing remote monitoring (RPM) markets for Biotricity’s technology: maternal and post-operative remote monitoring.

  • ACCESSWIRE8 months ago

    An Unknown Stock and a $50B Regulatory Trend Could Result in a Cannabis Like Breakout

    A major shift in healthcare could rival this new industry as the biggest health insurer in the U.S., Medicare & Medicaid, tries to save money by moving more procedures (and patients) out of hospitals into smaller surgical centers and get them out of the surgical setting rapidly. Medicare is already saving billions each year according to a recent study and is hoping to save almost $60 billion in the coming years through this huge cost cutting measure. Remote patient monitoring, already a big and lucrative business, is likely to become a whole lot larger.

  • GlobeNewswire9 months ago

    Distinguished Physicians Join Biotricity’s Newly Formed Scientific and Medical Alliance Board

    Biotricity Inc. (OTCQB: BTCY), a medical diagnostic and consumer healthcare technology company, today announced that Drs. Donald S. (Buck) Cross, Edward Lazaga, Imran Mohiuddin, Radoslaw (Stefan) Kiesz, and Tea Acuff will be joining the Company’s Scientific and Medical Alliance Board. “We are fortunate to add such high caliber physicians to our Scientific and Medical Alliance Board,” said Mr. Waqaas Al-Siddiq, Biotricity Founder and CEO. The Company is leveraging the success of its RPM platform within Bioflux and applying it in remote patient monitoring solutions for a wide array of chronic conditions that will help aid disease management and improve patient engagement.